| |
Odds ratios (95 % Cl) for interval versus screen-detected cancer, estimated by logistic regression modelling
|
|---|
|
Primary cohort
|
Validation cohort
|
|---|
|
Covariate
|
Model 1 n = 1403
|
Model 2 n = 1314
|
Model 3 n = 1312
|
Model 3 n = 1182
|
|
Percent density
|
1.37 (1.22 to 1.53)
|
1.23 (1.08 to 1.41)
|
0.98 (0,81 to 1.17)
|
1.04 (0.86 to 1.24)
|
|
BMI
|
-
|
0.84 (0.73 to 0.98)
|
0.88 (0.76 to 1.02)
|
0.98 (0.84 to 1.15)
|
|
HRT use at diagnosis
|
-
|
1.57 (1.17 to 2.11)
|
1.53 (1.14 to 2.07)
|
1.32 (0.99 to 1.77)
|
|
Age at diagnosis
|
-
|
0.98 (0.87 to 1.12)
|
1.01 (0.89 to 1.15)
|
0.90 (0.77 to 1.05)
|
|
F40 skewness of the intensity gradient
|
-
|
-
|
1.32 (1.12 to 1.56)
|
1.21 (1.04 to 1.41)
|
|
F21 eccentricity
|
-
|
-
|
1.20 (1.04 to 1.39)
|
1.17 (0.98 to 1.39)
|
- Feature values calculated based on the dense area of the mammogram as identified by Otsu's method, then Box-Cox transformed and standardized. Odds ratios are estimated as per-standard deviation change in the underlying covariate. Validation cohort is an older breast cancer cohort with similar covariate definitions as the primary cohort
-
1C interval breast cancer, SC screen-detected breast cancer, 95 % CI 95 % confidence interval, BMI body mass index, HRT hormone replacement therapy
